Hybrid split-arc partial-field volumetric modulated arc therapy: an improved beam arrangement for linear accelerator-based hippocampal-avoidance whole brain radiation therapy

Adams Hei Long Yuen O1,2, Po Man Wu1, Alex Kai Leung Li2, Philip Chung Yin Mak2

1Department of Diagnostic Radiology and Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China
2Oncology Centre, St. Teresa’s Hospital, Hong Kong Special Administrative Region, China

ABSTRACT

Background: This technical note aims to verify the hippocampus and adjacent organs at risk (OARs) sparing ability of an improved beam arrangement, namely hybrid split-arc partial-field volumetric modulated arc therapy (VMAT) (Hsapf-VMAT) during whole brain radiation therapy (WBRT).

Materials and methods: Computed tomography simulation images of 22 patients with brain metastases were retrieved in this retrospective planning study. The hippocampus was manually delineated according to the criterion of RTOG 0933. Plans delivering 30 Gy in 10 fractions were generated for each patient using split-arc partial-field VMAT (sapf-VMAT) and Hsapf-VMAT. The sapf-VMAT plans consisted of 4 arc fields of 179.9° each with reduced field size. The Hsapf-VMAT consisted of 4 arc fields similar to sapf-VMAT in addition to 2 lateral opposing static fields. Statistical comparisons between treatment plans of both techniques were performed using the paired t-test at 5% level significance.

Results: The results demonstrated that Hsapf-VMAT can achieve superior dose sparing in hippocampus which is comparable to sapf-VMAT (p > 0.05). In both eyes, Hsapf-VMAT had significantly lower Dmean and Dmax compared to sapf-VMAT (p < 0.005). Decrease in Dmax of both lenses using Hsapf-VMAT (p < 0.005) were statistically significant when compared to sapf-VMAT. Hsapf-VMAT demonstrated significant reduction of Dmean and Dmedian to the optic nerves (p < 0.05). Whole brain planning target volume (PTV) coverage was not compromised in both techniques.

Conclusion: The present study adopts a hybrid technique, namely Hsapf-VMAT, for hippocampal sparing WBRT. Hsapf-VMAT can achieve promising dose reduction to the hippocampus, both eyes and lenses. Therefore, Hsapf-VMAT can be considered an improved version of sapf-VMAT.

Key words: hippocampal sparing; static-field; partial-field; split-arc; volumetric modulated arc therapy; whole brain radiation therapy; neurocognitive deficit

Rep Pract Oncol Radiother 2022;27(2):352–359

Address for correspondence: Adams Hei Long Yuen, Oncology Centre, St. Teresa’s Hospital, 327 Prince Edward Road, Hong Kong Special Administrative Region, China; e-mail: yhladams@hotmail.com

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially

https://journals.viamedica.pl/rpor
Introduction

Radiation Therapy Oncology Group (RTOG) 0933, a phase II clinical trial, studies the effectiveness of hippocampal sparing during whole brain radiation therapy (WBRT) and has demonstrated promising results in preserving memory function using the dose criteria in the protocol (Supplementary File — Tab. S1) [1]. Recently, our oncology centre has employed both split-arc and partial-field techniques together to eliminate scatter radiation and overcome multileaf collimator (MLC) limitations in WBRT volumetric modulated arc therapy (VMAT) planning [2]. This technique has shown to be more advantageous in sparing hippocampus compared with conventional dual-arc VMAT, while the target coverage has not been compromised.

However, owing to the relatively low total prescription dose (30 Gy in 10 fractions) of WBRT, potential radiation-induced toxicity to organs at risk (OARs), in addition to hippocampus, can be overlooked and underestimated. In fact, radiation-induced toxicity to the adjacent OARs, including the eyes and lenses, during WBRT have been described in previous publications with negative impact on patients’ quality of life [3–6]. Previous publications have reported that radiation retinopathy can be induced with radiation dose as low as 18 Gy in patients with presence of comorbidities (such as compromised chorioretinal circulation) [7] or with exposure to radiation sensitizers (such as chemotherapy) [8]. In the meantime, radiation dose as low as 2 Gy may result in abnormalities of lens fibers, subsequently cataract [9]. Jeganathan et al. [10] have reported that there is a 66% risk of cataract progression if the lens receives radiation doses exceeding 6.5 Gy with a latency of 4 years. Therefore, radiation dose to the adjacent OARs, in addition to hippocampus, should also be considered and minimized during treatment planning of WBRT.

Using VMAT alone has been reported to produce a large volume of low dose region in the surrounding normal tissue [11–13]. In the meantime, the study of Wang et al. [14] has shown better eyes and lenses sparing using lateral opposing static fields. We, therefore, hypothesize that a hybrid technique, the combination of split-arc partial-field VMAT (sapf-VMAT) with lateral opposing static fields for hippocampal sparing WBRT may provide further improvement in OAR sparing while keeping enough dose coverage to the whole brain target volume.

This technical note has proposed an improved version of the split-arc partial-field VMAT (sapf-VMAT), namely hybrid split-arc partial-field VMAT (Hsapf-VMAT), for hippocampal sparing WBRT. The present study aims to compare the dosimetric parameters of Hsapf-VMAT with sapf-VMAT to verify its sparing ability to the hippocampus as well as to adjacent OARs during WBRT.

Materials and methods

Patient selection and computed tomography simulation

In the present retrospective planning study, 22 patients, who were previously treated with WBRT in 2012–2020, were randomly selected. During computed tomography (CT) simulation scan, patients were immobilized in a supine position on a dual-source CT scanner (SOMATOM Definition, Siemens Healthcare, Forchheim, Germany). Immobilization was achieved using Head & Neck Support Cushions and thermoplastic mask. The CT simulation images were transferred to the Eclipse™ (Varian Medical System, Palo Alto, CA) version 15.5 treatment planning system for WBRT planning.

Targets and OARs delineations

Six OARs were defined, including the eyes, lenses, optic nerves, optic chiasm, brainstem and hippocampus. To accurately identify the hippocampus as suggested by Gondi et al. [1], all patients underwent T1-weighted spoiled gradient-recalled echo magnetic resonance (MR) imaging, standard axial and fluid attenuation recovery (FLAIR) sequence and T2-weighted sequence. Automatic rigid registration was performed between CT simulation and MR images. Target and OARs delineations were made on CT simulation images based on co-registered T1-weighted cranial magnetic resonance images. To minimize inter-observer variability, the hippocampus was manually delineated by a radiation oncologist according to the criterion of RTOG 0933 (available at: http://www.rtog.org) (Supplementary File — Fig. S1).

The planning target volume (PTV) for optimization (whole brain PTV) was defined as the whole
brain volume subtracting the hippocampal planning risk volume. The hippocampal planning risk volume was generated by volumetrically isotropic 5mm expansion of hippocampus volume using the in-built expansion function of the planning system.

**Dose prescription**

The treatment prescription to the whole brain PTV was 30 Gy in 10 fractions. According to RTOG 0933, the minimum dose (D$_{100\%}$) and maximum dose (D$_{max}$) to the hippocampus were limited to 9 Gy and 17 Gy, respectively. The D$_{max}$ to the optic chiasm and optic nerves were limited to 37.5 Gy.

**Treatment planning**

Treatment plans were scheduled using Varian TrueBeam™ (Varian Medical Systems, Palo Alto, CA), Millennium 120-leaf MLC, jaw tracking, and 6-MV photon beams with a maximum dose rate of 600 MU/min. All treatment plans were normalized such that at least 97% of the whole brain PTV received 95% of the prescribed dose. To avoid bias, the present study standardized the optimization objectives between patients of each technique. The optimization objectives of major structures were illustrated in Supplementary File — Table S2. The anisotropic analytic algorithm (AAA, ver.15.5.11, Varian Medical Systems) was used for dose calculation with calculation grid of 1 mm.

**Split-arc partial-field VMAT (sapf-VMAT)**

The sapf-VMAT plans were created with reference to previous publication of our oncology centre [2]. Four VMAT arc fields of 179.9° were employed with collimator angle of 85°, 95°, 15° and 345°, respectively. Reduced field size was employed in each beam arc to spare the hippocampus while not sacrificing the whole brain PTV coverage. Detailed description of the sapf-VMAT beam arrangement was illustrated in Supplementary File — Figure S2A.

**Hybrid split-arc partial-field VMAT (Hsapf-VMAT)**

The Hsapf-VMAT consisted of 4 arc fields of 179.9° each and 2 lateral opposing static fields. The isocentre was the same as the sapf-VMAT plans. The beam arrangement of the static fields was in lateral opposing directions where the vast majority of whole brain PTV were covered by the beam axis. Collimator angles of 60° and 120° were chosen for the 2 static fields, so that both eyes were shielded by the X1 collimator jaw. MLC were used to minimize the irradiated hippocampus volume. The beam arrangement of lateral opposing static fields was illustrated in Supplementary File — Figure S3. The lateral opposing static fields plan was set to deliver 30% of the prescribed dose.

Using the lateral opposing static fields plan as a base plan, the 4 arc fields were optimized to sculpt the optimal conformity and organ sparing. The arc fields were arranged similarly to sapf-VMAT. Detailed description of the Hsapf-VMAT beam arrangement was illustrated in Supplementary File — Figure S2B.

**Treatment planning evaluation and quality assurance**

Dosimetric parameters of both techniques were extracted from the dose–volume histogram (DVH). Homogeneity index (HI) of whole brain PTV was evaluated [15] (Equation 1):

$$HI = \frac{(D_{2\%} - D_{98\%})}{D_{median}}$$  \hspace{1cm} (Equation 1)

MobiusCalc dose calculation verification system (version 2.1, Mobius Medical Systems, LP, Houston, TX) was used for quality assurance (QA) of treatment plans. All treatment plans were required to achieve a gamma value > 95% with tolerance for distance to agreement as 3 mm and dose difference as 3%.

**Statistical analyses**

Statistical comparisons between treatment plans of both techniques were performed using the paired t-test at 5% level significance.

**Results**

All treatment plans have achieved good correlation in QA. Dosimetric parameters were summarized as mean ± standard deviation (SD) (Tab. 1). DVH of the dosimetric parameters using sapf-VMAT and Hsapf-VMAT were compared (Fig. 1A). The average hippocampus volume was 3.80 cm$^3$ (ranged from 2.82–4.72 cm$^3$), the average hippocampal planning risk volume was 26.50 cm$^3$ (ranged from 23.06–30.03 cm$^3$), and the average whole brain PTV was 1232.05 cm$^3$ (ranged from 1050.93–1471.00 cm$^3$).
The isodose line diagram from 20 Gy to 37.5 Gy of both treatment techniques was illustrated in Figure 1B. All treatment plans were capable of achieving adequate target coverage. The maximum dose of whole brain PTV was less than 37.5 Gy in accordance to the RTOG 0933 protocol. With regard to the whole brain PTV coverage, Hsapf-VMAT provided an average $V_{30Gy}$ of 94.69%, which was comparable to sapf-VMAT (94.79%). No significant differences ($p > 0.05$) were observed between the treatment groups.

### Table 1. Averaged results and comparison of dosimetric parameters using split-arc partial-field VMAT (sapf-VMAT) and hybrid split-arc partial-field volumetric modulated arc therapy (Hsapf-VMAT). Each value was calculated based on the data from 22 patients and was expressed as mean ± standard deviation (SD)

| Structures                  | Dosimetric parameters | sapf-VMAT                      | Hsapf-VMAT                     | p-value |
|-----------------------------|-----------------------|--------------------------------|--------------------------------|---------|
| Whole brain PTV             | $V_{30Gy}$ (%), Gy, Gy | $94.79 ± 0.12$, $33.14 ± 0.33$, $25.87 ± 0.31$, $0.23 ± 0.01$, $31.33 ± 0.14$, $31.16 ± 0.13$ | $94.69 ± 0.15$, $33.28 ± 0.24$, $25.62 ± 0.22$, $0.24 ± 0.02$, $31.39 ± 0.08$, $31.14 ± 0.09$ | 0.358   |
| Hippocampus                 | Gy, %, %, Gy, Gy, %, Gy | $7.88 ± 0.04$, $13.26 ± 0.45$, $9.03 ± 0.13$, $9.17 ± 0.10$, $30.69 ± 0.45$ | $7.92 ± 0.09$, $13.31 ± 0.32$, $9.11 ± 0.09$, $9.21 ± 0.12$, $30.55 ± 0.56$ | 0.677   |
| Left optic nerve            | Gy, %, %, Gy, Gy, %, Gy | $30.29 ± 1.49$, $24.12 ± 1.01$, $30.37 ± 0.77$, $9.17 ± 0.10$, $30.69 ± 0.45$ | $20.90 ± 2.33$, $20.20 ± 1.71$, $30.41 ± 0.57$, $9.21 ± 0.12$, $30.55 ± 0.56$ | < 0.005** |
| Right optic nerve           | Gy, %, %, Gy, Gy, %, Gy | $32.50 ± 0.71$, $31.10 ± 0.40$, $31.11 ± 0.42$ | $32.37 ± 0.28$, $31.39 ± 0.27$, $31.34 ± 0.27$ | 0.461   |
| Optic chiasm                | Gy, %, %, Gy, Gy, %, Gy | $17.23 ± 0.56$, $9.87 ± 0.41$, $9.55 ± 0.41$, $17.18 ± 0.24$, $9.90 ± 0.51$, $9.27 ± 0.33$ | $12.26 ± 1.48$, $6.95 ± 0.14$, $7.18 ± 0.17$, $12.35 ± 1.05$, $7.01 ± 0.19$, $7.38 ± 0.56$ | < 0.005** |
| Left eye                    | Gy, %, %, Gy, Gy, %, Gy | $7.37 ± 0.26$, $5.72 ± 0.20$, $5.75 ± 0.19$, $7.43 ± 0.38$, $5.86 ± 0.26$, $5.90 ± 0.26$ | $5.82 ± 0.19$, $5.26 ± 0.17$, $5.28 ± 0.17$, $5.77 ± 0.16$, $5.22 ± 0.13$, $5.25 ± 0.11$ | < 0.005** |
| Right eye                   | Gy, %, %, Gy, Gy, %, Gy | $7.37 ± 0.26$, $5.72 ± 0.20$, $5.75 ± 0.19$, $7.43 ± 0.38$, $5.86 ± 0.26$, $5.90 ± 0.26$ | $5.82 ± 0.19$, $5.26 ± 0.17$, $5.28 ± 0.17$, $5.77 ± 0.16$, $5.22 ± 0.13$, $5.25 ± 0.11$ | < 0.005** |
| Total MU                    | MU, MU, MU, MU, MU, MU | $1087.58 ± 158.57$, $3.06 ± 0.23$, $3.64 ± 0.24$, $3.06 ± 0.23$, $3.64 ± 0.24$, $1093.78 ± 122.15$, $3.31 ± 0.16$, $4.80 ± 0.17$ | $1093.78 ± 122.15$, $3.31 ± 0.16$, $4.80 ± 0.17$, $1087.58 ± 158.57$, $3.06 ± 0.23$, $3.64 ± 0.24$ | 0.599   |
| Beam-on time (min)          | MU, MU, MU, MU, MU, MU | $3.06 ± 0.23$, $3.64 ± 0.24$, $3.06 ± 0.23$, $3.64 ± 0.24$, $1093.78 ± 122.15$, $3.31 ± 0.16$, $4.80 ± 0.17$ | $3.31 ± 0.16$, $4.80 ± 0.17$, $3.06 ± 0.23$, $3.64 ± 0.24$, $1087.58 ± 158.57$, $3.06 ± 0.23$, $3.64 ± 0.24$ | 0.157   |
| Delivery time (min)         | MU, MU, MU, MU, MU, MU | $3.06 ± 0.23$, $3.64 ± 0.24$, $3.06 ± 0.23$, $3.64 ± 0.24$, $1093.78 ± 122.15$, $3.31 ± 0.16$, $4.80 ± 0.17$ | $3.31 ± 0.16$, $4.80 ± 0.17$, $3.06 ± 0.23$, $3.64 ± 0.24$, $1087.58 ± 158.57$, $3.06 ± 0.23$, $3.64 ± 0.24$ | < 0.005** |

*p < 0.05; **p < 0.005 (paired t-test); PTV — planning target volume; $V_{30Gy}$ — percentage volume of whole brain PTV receiving dose at least 30 Gy; $D_{98\%}$ — dose to 2% of the whole brain PTV; $D_{98\%}$ — dose to 98% of the whole brain PTV; HI — homogeneity index; $D_{max}$ — maximum dose; $D_{mean}$ — mean dose; $D_{median}$ — median dose; MU — monitor unit

**Target coverage and dose homogeneity**

The isodose line diagram from 20 Gy to 37.5 Gy of both treatment techniques was illustrated in Figure 1B. All treatment plans were capable of achieving adequate target coverage. The maximum dose of whole brain PTV was less than 37.5 Gy in accordance to the RTOG 0933 protocol. With regard to the whole brain PTV coverage, Hsapf-VMAT provided an average $V_{30Gy}$ of 94.69%, which was comparable to sapf-VMAT (94.79%). No significant differences ($p > 0.05$) were observed between the treatment groups.
were found between Hsapf-VMAT vs. sapf-VMAT in V_{30Gy}. Mean HI of Hsapf-VMAT and sapf-VMAT were 0.24 and 0.23, respectively. No significant differences (p > 0.05) were found between both techniques.

**Hippocampus**

Hsapf-VMAT (7.92 Gy, p >0.05) had a comparable average D_{100%} to sapf-VMAT (7.88 Gy). There were also no significant differences (p > 0.05) between Hsapf-VMAT vs. sapf-VMAT in terms of hippocampus D_{max}, D_{median} and D_{mean}.

**Optic chiasm, optic nerves, eyes and lenses**

The average D_{max} to the optic chiasm in sapf-VMAT and Hsapf-VMAT was 32.50 Gy and 32.37 Gy, respectively (p > 0.05). Hsapf-VMAT was comparable to sapf-VMAT (p > 0.05) in averaged D_{max} for both optic nerves. However, Hsapf-VMAT demonstrated significantly lower D_{median} and D_{mean} to the optic nerves compared to sapf-VMAT (p < 0.05). In both eyes, Hsapf-VMAT demonstrated significantly lower D_{mean} and D_{max} compared to sapf-VMAT (p < 0.005). Hsapf-VMAT also had significantly lower lenses D_{max} compared to sapf-VMAT (p < 0.005).

**Total monitor unit, beam on time and delivery time**

The average total MU in Hsapf-VMAT (1093.78, p > 0.05) is comparable to sapf-VMAT (1087.58). The averaged beam-on time was 3.06 minutes and 3.31 minutes for sapf-VMAT and Hsapf-VMAT,
respectively. No significant differences \( (p > 0.05) \) were found between both techniques in beam-on time. The averaged treatment delivery time was 3.64 minutes and 4.80 minutes, respectively. Significant differences \( (p < 0.005) \) were found between both techniques in delivery time.

**Discussion**

In the present study, a hybrid technique named Hsapf-VMAT has been employed. This technique has consistently produced comparable hippocampus dose to sapf-VMAT and is less than the cutoff value of radiation induced neurocognitive deficit onset [1].

The RTOG 0933 protocol does not provide dosimetric criteria for both eyes and lenses. Several studies have reported that damages to eyes and lenses can be induced by radiation dose as low as 18 Gy [7, 8] and 6.5 Gy [10], respectively. Meanwhile, a previous study has shown that higher mean dose to the optic nerves is also associated with higher occurrence of ocular complications [16]. These data provide further support for the minimization of dose to the ocular and orbital organs in patients receiving WBRT. The results from the present study have revealed that Hsapf-VMAT, compared to sapf-VMAT, has demonstrated significant dose reduction to both eyes and lenses, in addition to the hippocampus. Such reduction is achievable since the eyes and lenses have been shielded by the X1 collimator jaw in the pair of static fields in which the beam weights were set to deliver 30\% of the prescribed dose (Supplementary File — Fig. S3). It indicates that Hsapf-VMAT may be capable of lowering the risk of radiation induced ocular and orbital morbidity as described in previous publications. This technique is especially important when the patient has existing comorbidity or exposure to radiation sensitizers [7, 8].

The beam arrangement of non-coplanar intensity modulated radiation therapy (nc-IMRT) recommended by the RTOG protocol have included seven or eight non-coplanar beams with the average treatment delivery time of 19 minutes [17]. In fact, intensity modulated radiation therapy itself has required significantly longer treatment delivery time and higher MU when compared to VMAT in brain tumor radiotherapy [18]. Meanwhile, the application of non-coplanar beams may further increase the treatment delivery time [19]. The associated increased treatment time can potentially lead to the possibility of intra-fraction motion. As treatment times are compounded daily, the potential intra-fractional error needs to be weighed against the benefit to the individual patient. In the present study, six coplanar treatment fields (4 arc fields and 2 static fields) were used for Hsapf-VMAT with an average treatment delivery time of 4.8 minutes. Although properties of nc-IMRT has not been compared to Hsapf-VMAT in the present study, Hsapf-VMAT seemingly required less treatment delivery time, since non-coplanar beam has not been used. Extension of this research could examine the dosimetric and treatment properties, including treatment delivery time and intra-fractional error, of Hsapf-VMAT and nc-IMRT.

Admittedly, using Helical Tomotherapy (HT) with a complete directional block technique might achieve lower eyes and lenses dose than Hsapf-VMAT in the present study. However, the improved eyes and lenses doses are also at the expense of substantial increased treatment time [20]. Meanwhile, due to the high machine procurement and maintenance cost [21], HT may not be extensively available as a linear accelerator. Therefore, delivery of Hsapf-VMAT using linear accelerator is still an efficient and cost-effective option for many clinical settings.

There have been no previous reports that examined the optimal proportion for static fields/arc fields during hybrid-VMAT WBRT. In the present study, the preferable weighting proportion of static fields and VMAT in Hsapf-VMAT for WBRT is 30\% and 70\%, respectively. Increased proportion of static fields during trial have shown to reduce the conformity and homogeneity of the treatment plans, while increased proportion of arc fields have demonstrated reduced dose sparing in the optic nerves, eyes and lenses. Further knowledge on the relationship of static fields/arc fields weighting may allow the application of Hsapf-VMAT to other brain tumors.

**Limitation**

Manual delineation of the hippocampus poses technical challenges for oncologists, medical physicists, dosimetrists and radiation therapists with
high inter-observer variability [22, 23]. In our oncology centre, to minimize hippocampus contouring uncertainty during treatment planning, hippocampal volume must be delineated by oncologists with at least 5 years of post-specialization experience. To prevent inter-observer variability arising in the present study, the hippocampus was manually delineated by only a single radiation oncologist with more than 10 years of post-specialization experience.

Dose reduction in the optic nerves, eyes and lenses using Hsapf-VMAT may prevent undesirable ocular and orbital morbidity; however, the biological effect of this technique has not been studied in the present technical report. In the future, meta-analysis will be crucial to confirm the clinical usability and functional outcome of Hsapf-VMAT. In the meantime, the benefit of Hsapf-VMAT is at the cost of increased time required for treatment delivery. In the present study, the averaged treatment delivery time of Hsapf-VMAT plans is around 70 seconds longer than the sapf-VMAT plans. The increased treatment time is primarily due to the additional gantry travel time for the lateral opposing static fields. Nonetheless, a more advanced optimization system in the future may be capable of achieving comparable plan quality with reduced treatment time.

Conclusion

The present study adopts a hybrid technique, namely Hsapf-VMAT, for hippocampal sparing WBRT. This technique has taken advantage of both lateral opposing static fields and sapf-VMAT. Hsapf-VMAT has demonstrated comparable hippocampus dose to sapf-VMAT, while achieving dose reduction in the eyes and lenses. Therefore, Hsapf-VMAT can be considered an improved version of sapf-VMAT.

Ethics approval and consent to participate
All procedures in this study were reviewed and approved by the University of Hong Kong and the Oncology Centre, St. Teresa’s Hospital (HKSAR).

Consent for publication
Publication of this study was approved by the University of Hong Kong and the Oncology Centre, St. Teresa’s Hospital (HKSAR).

Availability of data and materials
The data that support the findings of this study are available from the Oncology Centre, St. Teresa’s Hospital (HKSAR) but restrictions apply to the availability of these data, which were used under permission for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the Oncology Centre, St. Teresa’s Hospital (HKSAR) at the following e-mail address: st-hochk@gmail.com.

Conflict of interests
None declared.

Funding
The authors declare no competing financial interests.

Authors’ contributions
Conception and design of the study — AHLY, AKLL; acquisition of data — AHLY, AKLL, PCYM; analysis and interpretation of data — AHLY, PCYM; drafting and revising the article — AHLY; final approval of the manuscript — AKLL, PMW, AHLY

Acknowledgements
The authors would like to thank the editor and anonymous reviewer for their constructive comments. The authors would also like to thank the Oncology Centre, St. Teresa’s Hospital (HKSAR) for providing access to the treatment planning system and patient data. Sincere appreciation is also extended to Dr. Gordon Kwok Hung Au, Dr. Thomas Man Cheuk Ng, Mr. Yan Kit Wah, Mr. To Wing Mok, Ms. Tik Yean Nam and Dr. Wincy Wing Sze Wong, Mr. Hinnyque Hip Lap Leung for their assistance in data collection and comments on dosimetric planning. Special thanks to Mr. Chu King-Shan for English editing of this manuscript.

References
1. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933); a phase II multi-institutional trial. J Clin Oncol. 2014; 32(34); 3810–3816, doi: 10.1200/JCO.2014.57.2909, indexed in Pubmed: 25349290.
2. Yuen AHL, Wu PM, Li AKL, et al. Volumetric modulated arc therapy (VMAT) for hippocampal-avoidance whole brain
radiation therapy: planning comparison with Dual-arc and Split-arc partial-field techniques. Radiat Oncol. 2020; 15(1): 42, doi: 10.1186/s13014-020-01488-5, indexed in Pubmed: 32070385.

3. Hsu CR, Tai MC, Chang YH, et al. Rapid onset of radiation maculopathy after whole-brain radiation therapy: A case report. Medicine (Baltimore). 2016; 95(39): e4830, doi: 10.1097/MD.0000000000004830, indexed in Pubmed: 27684815.

4. Tobillo R, Pearlstein K, Mahbooba Z, et al. Dry eye after whole brain radiation: Analysis from a prospective study. J Clin Oncol. 2018; 36(34_suppl): 198–198, doi: 10.1200/jco.2018.36.34_suppl.198.

5. Park J, Park JW, Yea JiW. Non-coplanar whole brain radiotherapy is an effective modality for parotid sparing. Yeungnam Univ J Med. 2019; 36(1): 36–42, doi: 10.12701/yujm.2019.00087, indexed in Pubmed: 31620610.

6. Fang K, Tobillo R, Mavroidis P, et al. Prospective Assessment of Patient-Reported Dry Eye Syndrome After Whole Brain Radiation. Int J Radiat Oncol Biol Phys. 2019; 105(4): 765–772, doi: 10.1016/j.ijrobp.2019.07.015, indexed in Pubmed: 31351194.

7. Finger PT. Radiation therapy for orbital tumors: concepts, current use, and ophthalmic radiation side effects. Surv Ophthalmol. 2009; 54(5): 545–568, doi: 10.1016/j.survophthal.2009.06.004, indexed in Pubmed: 19682622.

8. Finger PT. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys. 2008; 70(4): 974–977, doi: 10.1016/j.ijrobp.2007.11.045, indexed in Pubmed: 18313522.

9. Scoccianti S, Detti B, Gadda D, et al. Organs at risk in the brain and their dose-constraints in adults and in children: a radiation oncologist’s guide for delineation in everyday practice. Radiother Oncol. 2015; 114(2): 230–238, doi: 10.1016/j.radonc.2015.01.016, indexed in Pubmed: 25671297.

10. Jeganathan VS, Wirth A, MacManus MP. Ocular risks from orbital and periorbital radiation therapy: a critical review. Int J Radiat Oncol Biol Phys. 2011; 79(3): 650–659, doi: 10.1016/j.ijrobp.2010.09.056, indexed in Pubmed: 21281895.

11. Wagner D, Christiansen H, Wolff H, et al. Radiotherapy of malignant gliomas: comparison of volumetric single arc technique (RapidArc), dynamic intensity-modulated technique and 3D conformal technique. Radiother Oncol. 2009; 93(3): 593–596, doi: 10.1016/j.radonc.2009.10.002, indexed in Pubmed: 19897266.

12. Wolff D, Stieler F, Welzel G, et al. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol. 2009; 93(2): 226–233, doi: 10.1016/j.radonc.2009.08.011, indexed in Pubmed: 19765846.

13. Chan OSH, Lee MCH, Hung AWM, et al. The superiority of hybrid-volumetric arc therapy (VMAT) technique over double arcs VMAT and 3D-conformal technique in the treatment of locally advanced non-small cell lung cancer—a planning study. Radiother Oncol. 2011; 101(2): 298–302, doi: 10.1016/j.radonc.2011.08.015, indexed in Pubmed: 21907438.

14. Wang BH, Hua W, Gu X, et al. Dosimetric study of different radiotherapy planning approaches for hippocampal avoidance whole-brain radiation therapy (HA-WBRT) based on fused CT and MRI imaging. Australas Phys Eng Sci Med. 2015; 38(4): 767–775, doi: 10.1007/s13246-015-0397-7, indexed in Pubmed: 26577714.

15. International Commission on Radiation Units and Measurements Report 83. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). J ICRU. 2010; 10.

16. Martel MK, Sandler HM, Cornblath WT, et al. Dose-volume complication analysis for visual pathway structures of patients with advanced paranasal sinus tumors. Int J Radiat Oncol Biol Phys. 1997; 38(2): 273–284, doi: 10.1016/s0360-3016(97)00029-1, indexed in Pubmed: 9226313.

17. Andreas JJ, Kundapur V. Hippocampus Avoidance Whole-brain Radiation Therapy: A Practical Intensity-modulated Radiation Therapy Planning and Delivery Approach to RTOG 0933. J Med Imaging Radiat Sci. 2015; 46(1): 78–84, doi: 10.1016/j.jmir.2014.09.009, indexed in Pubmed: 31052068.

18. Panet-Raymond V, Ansbacher W, Zavgorodni S, et al. Coplanar versus noncoplanar intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) treatment planning for fronto-temporal high-grade glioma. J Appl Clin Med Phys. 2012; 13(4): 3826, doi: 10.1120/jacmp.v13i4.3826, indexed in Pubmed: 22766954.

19. De Ruyscher D, Faire-Finn C, Moeller D, et al. Lung Group and the Radiation Oncology Group of the European Organization for Research and Treatment of Cancer (EORTC). European Organisation for Research and Treatment of Cancer recommendations for planning and delivery of high-dose, high-precision radiotherapy for lung cancer. J Clin Oncol. 2010; 28(36): 5301–5310, doi: 10.1200/jco.2010.30.3271, indexed in Pubmed: 21079134.

20. Rong Yi, Evans J, Xu-Welliver M, et al. SU-E-T-581: Planning Evaluation of Step-And-Shoot IMRT, RapidArc and Helical TomoTherapy for Hippocampal-Avoidance Whole Brain Radiotherapy (HA-WBRT). Med Phys. 2012; 39(6Part19): 3839, doi: 10.1118/1.4735670, indexed in Pubmed: 28517063.

21. Yang ZX, Shen JT, Li YP, et al. Rapid Health Technology Assessment Working Group of Chinese Evidence-Based Medicine Centre. Helical tomotherapy for cancer treatment: a rapid health technology assessment. J Evid Based Med. 2014; 7(3): 192–218, doi: 10.1111/jebm.12109, indexed in Pubmed: 25156336.

22. Bartel F, van Herk M, Vrenken H, et al. Inter-observer variation of hippocampus delineation in hippocampal avoidance prophylactic cranial irradiation. Clin Transl Oncol. 2019; 21(2): 178–186, doi: 10.1007/s12094-018-1903-7, indexed in Pubmed: 29876759.

23. Konopka-Filippow M, Sierko E, Wojtukiewicz M. Benefits and difficulties during brain radiotherapy planning with hippocampus sparing. Oncol Clin Pract. 2019; 15(2): 104–110, doi: 10.5603/ocp.2019.0019.